Replimune Group (NASDAQ:REPL) CFO Emily Luisa Hill Sells 11,448 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 11,448 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56. Following the transaction, the chief financial officer directly owned 225,108 shares of the company’s stock, valued at approximately $2,919,650.76. This represents a 4.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Trading Up 11.6%

Shares of REPL stock opened at $15.24 on Thursday. The firm’s 50-day simple moving average is $10.44 and its 200-day simple moving average is $7.69. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $15.68. The firm has a market cap of $1.28 billion, a P/E ratio of -4.51 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last released its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). As a group, equities analysts forecast that Replimune Group, Inc. will post -2.7 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on REPL shares. Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a report on Wednesday. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Wolfe Research upgraded Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. raised their price objective on Replimune Group from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Replimune Group presently has an average rating of “Moderate Buy” and a consensus target price of $11.86.

Replimune Group News Roundup

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million financing strengthens liquidity: Replimune priced a $150 million underwritten offering, giving the clinical-stage biotechnology company additional capital to fund development of its oncology pipeline and lead candidate RP1. The financing appears to have eased concerns about near-term funding needs, although it may dilute existing shareholders. Replimune Announces Pricing of $150 Million Underwritten Offering
• Positive Sentiment: Analysts raised ratings and price targets: Wedbush, Leerink Partners and JPMorgan recently became more bullish on REPL. JPMorgan lifted its target to $20, while Leerink raised its target to $17 and upgraded the shares to outperform. Cantor Fitzgerald also maintained an overweight rating. This improving analyst stance suggests greater confidence in Replimune’s prospects, though the reported consensus target of $11.86 is below the current trading range. Replimune Shares Rise After Pricing of Offering
• Neutral Sentiment: Executives sold shares for tax obligations: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos collectively sold approximately 69,868 shares worth about $906,000 at an average price of $12.97. The SEC filings state that the sales covered tax withholding related to vested equity awards, and each executive retained a substantial position. As a result, the transactions offer limited evidence of weakening confidence, but could still draw investor attention after the stock’s recent advance. SEC insider transaction filing
• Negative Sentiment: Multiple law firms publicized a securities class action: Lawsuits filed on behalf of investors who purchased REPL securities between October 20, 2025, and April 10, 2026, allege that Replimune misled investors about RP1’s efficacy, commercial viability and unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and October 5, 2026 is the lead-plaintiff deadline. The allegations have not been proven, but the litigation adds legal, financial and reputational uncertainty. Replimune securities class action notice

Institutional Trading of Replimune Group

Several large investors have recently added to or reduced their stakes in REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after purchasing an additional 6,653 shares during the period. Millennium Management LLC boosted its position in shares of Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after buying an additional 33,574 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after buying an additional 119,145 shares during the period. Rhumbline Advisers grew its stake in shares of Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after buying an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. grew its stake in shares of Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after buying an additional 18,263 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.